Adagene Inc Earnings
The next earnings date for Adagene Inc has not yet been scheduled.
Analyst Estimates of Adagene Inc Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Adagene Inc Earnings: Historical
| 04/01/2026 | --- | $0 | 100.00% |
| 12/03/2025 | --- | $0 | 100.00% |
| 08/12/2025 | --- | $-0.23 | 30.30% |
| 05/28/2025 | --- | $-0.17 | 0.00% |
| 03/24/2025 | --- | $-0.29 | 38.30% |
| 11/27/2024 | --- | $0 | --- |
| 07/25/2024 | --- | $-0.29 | -9.62% |
| 05/29/2024 | --- | $0 | --- |
| 03/29/2024 | --- | $-0.27 | 0.00% |
| 11/29/2023 | --- | $-0.42 | 0.00% |
More About Adagene Inc
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
“Adagene Inc Earnings” Can Refer to the Adagene Inc Earnings Date
Some people say “Adagene Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Adagene Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Adagene Inc Stock on the Earnings Date
If you own Adagene Inc stock (ADAG) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Adagene Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Adagene Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Adagene Inc Earnings
You can contact us any time if you would like to ask questions about Adagene Inc earnings or anything else related to the stock market.